Investigating the Therapeutic Potential of a Polyherbal Formulation in Progesterone-induced Obesity: Insights from Preclinical Studies.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Devendra Shriram Shirode, Aishwarya Sambhaji Patil, Deepak S Khobragade, Sunil Kumar Kadiri, Prashant Tiwari
{"title":"Investigating the Therapeutic Potential of a Polyherbal Formulation in Progesterone-induced Obesity: Insights from Preclinical Studies.","authors":"Devendra Shriram Shirode, Aishwarya Sambhaji Patil, Deepak S Khobragade, Sunil Kumar Kadiri, Prashant Tiwari","doi":"10.2174/0115748863396631251005190202","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic disorders have grown more common, with obesity representing a significant chronic illness that leads to various severe health complications. The Obesity Atlas 2022 predicts one billion obese people by 2030. Contributors to obesity encompass heightened oxidative stress, hyperlipidemia, hunger enhancement, fat accumulation, insulin resistance, and diminished caloric expenditure. Numerous synthetic interventions for obesity are accessible today ; nonetheless, they frequently entail detrimental side effects. This research aimed to investigate the formulation of a prospective anti-obesity drug derived from plant origins.</p><p><strong>Methods: </strong>The anti-obesity effectiveness of a polyherbal formulation, derived from the ethanolic extract of both Hugonia mystax and Blumea lacera in a 1:1 ratio, was assessed in female mice with progesterone-induced obesity.</p><p><strong>Results: </strong>The preliminary phytochemical screening of the formulation specifies the presence of phenolic acids, flavonoids, and tannins. In accordance to OECD recommendations, 200 mg/kg and 400 mg/kg were designated after performing acute oral toxicity assessment as a low dose and high dose. During the study, body weight, BMI, abdomen circumference, glucose levels, lipid profile, SGOT, SGPT, atherogenic index, lipid peroxidation (LPO), and glutathione (GSH) levels were evaluated in all groups. The treatment markedly corrected the abnormal levels of these parameters and dramatically restored GSH levels.</p><p><strong>Discussion: </strong>Metabolic disorders, especially obesity, are increasing globally. Synthetic therapies have negative consequences; therefore, exploration of plant substitutes is encouraged A polyherbal extract of Hugonia mystax and Blumea lacera has shown significant anti-obesity properties in mice. It restored biochemical parameters, likely due to phytochemicals such as polyphenols. Histological examination validated its therapeutic efficacy.</p><p><strong>Conclusion: </strong>The formulation's efficacy in addressing obesity is likely attributable to the presence of polyphenols, saponins, and terpenoids. Histopathological examination of hepatic and adipose tissues further corroborated the anti-obesity efficacy of the polyherbal formulation. Future research will focus on isolating and identifying the active chemicals in both plants to better understand their composition.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863396631251005190202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Metabolic disorders have grown more common, with obesity representing a significant chronic illness that leads to various severe health complications. The Obesity Atlas 2022 predicts one billion obese people by 2030. Contributors to obesity encompass heightened oxidative stress, hyperlipidemia, hunger enhancement, fat accumulation, insulin resistance, and diminished caloric expenditure. Numerous synthetic interventions for obesity are accessible today ; nonetheless, they frequently entail detrimental side effects. This research aimed to investigate the formulation of a prospective anti-obesity drug derived from plant origins.

Methods: The anti-obesity effectiveness of a polyherbal formulation, derived from the ethanolic extract of both Hugonia mystax and Blumea lacera in a 1:1 ratio, was assessed in female mice with progesterone-induced obesity.

Results: The preliminary phytochemical screening of the formulation specifies the presence of phenolic acids, flavonoids, and tannins. In accordance to OECD recommendations, 200 mg/kg and 400 mg/kg were designated after performing acute oral toxicity assessment as a low dose and high dose. During the study, body weight, BMI, abdomen circumference, glucose levels, lipid profile, SGOT, SGPT, atherogenic index, lipid peroxidation (LPO), and glutathione (GSH) levels were evaluated in all groups. The treatment markedly corrected the abnormal levels of these parameters and dramatically restored GSH levels.

Discussion: Metabolic disorders, especially obesity, are increasing globally. Synthetic therapies have negative consequences; therefore, exploration of plant substitutes is encouraged A polyherbal extract of Hugonia mystax and Blumea lacera has shown significant anti-obesity properties in mice. It restored biochemical parameters, likely due to phytochemicals such as polyphenols. Histological examination validated its therapeutic efficacy.

Conclusion: The formulation's efficacy in addressing obesity is likely attributable to the presence of polyphenols, saponins, and terpenoids. Histopathological examination of hepatic and adipose tissues further corroborated the anti-obesity efficacy of the polyherbal formulation. Future research will focus on isolating and identifying the active chemicals in both plants to better understand their composition.

研究一种复方黄体酮诱导肥胖的治疗潜力:来自临床前研究的见解。
导言:代谢紊乱变得越来越普遍,肥胖是一种重要的慢性疾病,可导致各种严重的健康并发症。《2022年肥胖地图集》预测,到2030年,肥胖人口将达到10亿。导致肥胖的因素包括氧化应激升高、高脂血症、饥饿感增强、脂肪积累、胰岛素抵抗和热量消耗减少。今天有许多针对肥胖的综合干预措施;然而,它们往往会带来有害的副作用。本研究旨在研究从植物中提取的抗肥胖药物的配方。方法:以黄体酮致肥胖雌性小鼠为实验对象,研究了以黄体酮诱导的肥胖雌性小鼠为实验对象,采用从黄体酮诱导的肥胖雌性小鼠中提取的黄腐花和蓝腐花乙醇提取物按1:1比例提取的复方中药制剂的抗肥胖效果。结果:初步的植物化学筛选确定了该制剂中酚酸、类黄酮和单宁的存在。根据经合组织的建议,在进行急性口服毒性评估后,指定200毫克/公斤和400毫克/公斤为低剂量和高剂量。在研究期间,对所有组的体重、BMI、腹部围、血糖水平、脂质谱、SGOT、SGPT、动脉粥样硬化指数、脂质过氧化(LPO)和谷胱甘肽(GSH)水平进行评估。治疗显著纠正了这些参数的异常水平,并显著恢复了GSH水平。讨论:代谢性疾病,尤其是肥胖症,在全球范围内呈上升趋势。综合疗法有负面后果;因此,鼓励植物替代品的探索。一种多草药提取物Hugonia mystax和Blumea lacera在小鼠中显示出显著的抗肥胖特性。它恢复了生化参数,可能是由于植物化学物质,如多酚。组织学检查证实了其治疗效果。结论:该配方对肥胖的功效可能归因于其多酚、皂苷和萜类化合物的存在。肝脏和脂肪组织的组织病理学检查进一步证实了复方的抗肥胖功效。未来的研究将集中在分离和鉴定两种植物中的活性化学物质,以更好地了解它们的组成。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书